Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Health, Eone-Diagnomics Genome Center Ink Liquid Biopsy Partnership

NEW YORK – Molecular Health said Wednesday that is collaborating with South Korea's Eone-Diagnomics Genome Center (EDGC) to create a combined offering for precision oncology testing.

Specifically, the companies are pairing Molecular Health’s MH Guide software and EDGC’s OncoCatch-CDx assay, which analyzes circulating tumor DNA using next-generation sequencing in-house bioinformatics.

A joint venture established in 2013, EDGC currently provides a variety of clinical and consumer genetics products and services in addition to liquid biopsy, including noninvasive prenatal testing, newborn genetic screening, and a direct-to-consumer assay called Gene2me that assesses patients' cancer risk status.

Under the partnership with Molecular Health, EDGC will utilize that firm's analysis software, which automatically identifies genetic variants that are relevant for the treatment of cancer patients, to support reporting of OncoCatch-CDx results to ordering clinicians.

Financial terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.